SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

IINN

Inspira Technologies
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Watch for revenue recognition from the $49.5M in purchase orders in 2026 and any updates on strategic alternatives. The stock may react positively if procurement conversions accelerate, but remains high-risk due to minimal current revenue and history of losses.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.3930
T+0 close · Mar 26, 2026 · via day close
Latest settled
+332.57%
T+60 · $1.70
Vs SPY
+316.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $0.3930entry
  2. T+1 · 8mo ago +1.02%α +1.38% · $0.3970
  3. T+5 · 8mo ago +4.58%α +0.72% · $0.4110
  4. T+20 · 7mo ago +29.52%α +16.78% · $0.5090
  5. T+60 · 5mo ago +332.57%α +316.64% · $1.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inspira Technologies reported minimal revenue of $289,000 in 2025 with a net loss of $13.22 million, reflecting ongoing commercialization challenges. Despite the weak financials, the company secured $49.5 million in binding purchase orders expected to drive revenue in 2026 and raised $4.75 million in a follow-on offering, improving liquidity and Nasdaq compliance. Clinical deployments are expanding, and the company is advancing its HYLA blood sensor platform.

Key Financial Metrics

Revenue
$289.0K
EPS
$-1.32
Deal Value
$49.5M

Key Facts

  • Reported $289,000 in revenue for 2025, up from $0 in 2024
  • Net loss widened to $13.22 million in 2025 from $11.05 million in 2024
  • Secured $49.5 million in binding purchase orders, with revenue expected in 2026
  • Raised $4.75 million in a registered direct offering post-year-end
  • Cash and equivalents dropped to $3.16 million from $5.78 million in 2024
  • Appointed new VP of Global Sales and expanded clinical use at U.S. medical centers
  • Terminated non-binding term sheet with Bio-View Ltd., evaluating other strategic options

Financial Impact

Revenue of $289,000 is negligible; $49.5M in future orders represents significant potential upside in 2026

revenuecashnet lossdilution

Risk Factors

  • Minimal current revenue and sustained losses raise sustainability concerns
  • Revenue from $49.5M in orders is deferred and subject to procurement delays
  • High share-based compensation and executive turnover may signal governance risks

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263441

US Market Status

Market Closed · Opens in 9h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026